N/A N=20 Perinatal Stroke: Understanding Brain Reorganization
Stroke · Hemiparesis
Primary: Cortical Excitability MEP Amplitude (µV) — 325 µV
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Perinatal Arterial Stroke Treated With Stromal Cells Intranasally
Perinatal Arterial Ischemic Stroke · Neonatal Stroke
Primary: Number of Participants With Adverse Events Related to Intranasal MSC Treatment (Safety and Tolerability) in the Acute Setting. — 10; 0; 9; 1 Participants
Phase 2 N=256 Effects of Delayed Cord Clamp and/or Indomethacin on Preterm Infant Brain Injury
Intraventricular Hemorrhage · Periventricular Leukomalacia · Brain Injury
Primary: Percent of Survivors With no Severe IVH (Grades 3 or 4) or PVL — 22.2; 14.9; 17.1; 10.9 percent of participants
Phase 2 N=40 Percutaneous Recanalization in Ischemic Stroke Management (PRIISM): A Feasibility Clinical Study
Ischemic Stroke
Primary: Technical Device Success by as Assessed by the Percentage of Participants Which Established at Least TIMI 2 Flow Upon Deployment of the System Across the Occlusion and…
N/A N=111 Cerebral Oxygenation and Autoregulation in Preterm Infants
Intraventricular Hemorrhage of Prematurity · Complications of Prematurity
Primary: Mortality Before Hospital Discharge — 11 Participants
Phase 1 N=24 A Phase Ib/II in Patients With Acute Ischemic Stroke
Ischemic Stroke
Primary: Maximum Tolerated Dose (MTD) of DDFPe Evaluated by Number of Dose Limiting Toxicities — 0; 0; 0; 0 Dose Limiting Toxicities
Phase 2 N=65 Argatroban Stroke Treatment - A Pilot Safety Study
Ischemic Stroke
Primary: Symptomatic and Radiographic Intracerebral Hemorrhage — 6.2 percentage of patients
N/A N=2 Pilot Study of Pre-Ischemic Conditioning for Intracranial Atherosclerosis
Intracranial Atherosclerosis
Primary: Percent Change in Cerebral Blood Flow (CBF) — 0; 25 percentage increase in CBF
Phase 3 N=1 CEUS Evaluation of Hypoxic Ischemic Injury
Hypoxic-Ischemic Encephalopathy · Brain Ischemia Hypoxia
Primary: Detection of Brain Perfusion Abnormalities Using Contrast-enhanced Ultrasound — 1; 0 Participants
Phase 2 N=28 Mild Encephalopathy in the Newborn Treated With Darbepoetin
Neonatal Encephalopathy · Hypoxic-Ischemic Encephalopathy Mild
Primary: Normal Neurodevelopment — 13; 14 Participants
N/A N=666 ASPIRIN: Neurodevelopmental Follow-up Trial
Neurodevelopmental Abnormality
Primary: Bayley Scales of Infant and Toddler Development, 3rd Edition (Bayley-III) Cognitive Composite Score — 96; 96.8 score on a scale — p=0.25
N/A N=52 Surgical Indirect Revascularization For Symptomatic Intracranial Arterial Stenosis
Intracranial Arterial Stenosis · Intracranial Atherosclerosis · Ischemic Stroke
Primary: Stroke or Death in the Territory of Qualifying Artery — 5 Participants — p=0.08
Phase 4 N=457 Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II
Cerebral Infarction · Atherosclerosis
Primary: Number of Participants With Progression of Symptomatic Intracranial Stenosis — 20; 32 participants
N/A N=82 An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis
Intracranial Atherosclerosis
Primary: Successful Wingspan™ Stent Implantation (Access to the Lesion With the Stent, Accurate Deployment of the Stent Across the Target Lesion) — 78 patients w stent implanted
N/A N=480 Maternal Lifestyle and Neonatal Hypoglycemia
Hyperinsulinemia · Miscarriages · Pregnancy
Primary: Neonatal Hypoglycemia — 3; 15 neonates
Phase 2 N=31 NeuroCognition After Carotid Recanalization
Cognition Disorder · Stroke · Occlusion Carotid
Primary: Change in Montreal Cognitive Assessment (MoCA) Score — 0.56; 1.38; -0.75; 0.50 score on a scale
Phase 3 N=451 Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis
Ischemic Stroke
Primary: Any Stroke or Death Within 30 Days of Enrollment or Any Revascularization Procedure OR an Ischemic Stroke in the Territory of the Symptomatic Intracranial Artery Beyond…
Phase 4 N=203 Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler
Cerebral Infarction
Primary: The Changes of Middle Cerebral Artery (MCA) and Basilar Artery (BA) Pulsatility Index (PI) at 14 and 90 Days From the Baseline Transcranial Doppler (TCD) Study — 0.07…
N/A N=377 Age of Red Blood Cells in Premature Infants Study (ARIPI)
Premature Birth
Primary: 1. Composite Outcome of Necrotizing Enterocolitis, Intraventricular Hemorrhage, Bronchopulmonary Dysplasia and Retinopathy of Prematurity at 30 and 90-days. 2. Mortality…
N/A N=113,035 Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization
Stroke
Primary: All-cause Mortality During Hospitalization of Acute Ischemic Stroke (AIS) Patients — 2.6; 0.8 Percentage of participants
N/A N=12,551 1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients
Stroke
Primary: All-cause Mortality at 1 Year (Percentage of Patients With Modified Rankin Scale (mRS) Score =6) — 11.1; 12.2 Percentage of Participants — p=0.183
Phase 2 N=277 Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Acute Ischemic Stroke
Primary: Percentage of Participants With Composite Global Measure of Functional Disability Excellent Outcome at Day 90 — 54.1; 41.5; 39.9 percentage of participants — p=0.086
N/A N=980 Patent Foramen Ovale Closure or Medical Therapy After Stroke - RESPECT Trial
Cryptogenic Stroke
Primary: Composite of Recurrent Nonfatal Ischemic Stroke, Fatal Ischemic Stroke, or Early Death After Randomization — 9; 16 Participants — p=0.08
Phase 2 N=18 The Darbepoetin Alfa for Ischemic Surgical Complications (DISC) Dose Finding Trial
Spinal Ischemia · Stroke · Neuroprotection
Primary: Death or Neurologic Disability, Defined as an National Institutes of Health Stroke Scale (NIHSS)>4 or American Spinal Injury Association (ASIA) Lower Extermity Motor…
N/A N=16 American Heart Association- Stroke/Hypoxia Study
Stroke
Primary: Number of Participants With Adverse Events — 1; 11; 2; 10 Participants
Phase 3 N=3,876 Insulin Resistance Intervention After Stroke Trial
Stroke · Myocardial Infarction · Diabetes
Primary: Recurrent Fatal or Non-fatal Stroke, or Fatal or Non-fatal Myocardial Infarction — 175; 228 participants — p=.0067
Phase 2 N=125 Study to Assess the Safety and Effectiveness of the Penumbra System
Stroke
Primary: Percentage of Participants With Revascularization of the Occluded Target Vessel — 81.2 Percentage of Participants
N/A N=77 Brain Imaging and Developmental Follow up of Infants Treated With Erythropoietin
Prematurity
Primary: Full Scale IQ, Performance IQ, Verbal IQ, Executive Function — 79; 91; 103; 83 standardized score on a scale
Phase 3 N=500 High-dose Erythropoietin for Asphyxia and Encephalopathy
Neonatal Encephalopathy · Birth Asphyxia
Primary: Number of Participants With Death or Neurodevelopmental Impairment — 126; 110 Participants
Phase 3 N=93 Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events
Stroke · Myocardial Infarctions
Primary: PFA1 — 202.0; 271.1; 234.7 seconds — p=0.0742